STOCK TITAN

Atrion Reports First Quarter 2024 Results

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Negative)
Tags
Rhea-AI Summary

Atrion (NASDAQ: ATRI) reported first quarter 2024 results with revenues of $47.3 million, operating income of $3.1 million, and net income of $2.8 million. Diluted earnings per share were $1.59. Despite revenue growth and increased operating income, net income decreased due to a one-time inventory write-off. Gross margins declined primarily due to delayed orders, excess inventory, and product mix. The company remains debt free with total cash and investments of $18.7 million.

Positive
  • None.
Negative
  • One-time inventory write-off impacting operating income and net income.

  • Decrease in gross margins due to delayed orders, excess inventory, and product mix.

  • 20% decline in net income for the quarter.

Insights

Atrion Corporation's announcement displays mixed signals in its Q1 2024 performance. On one hand, the 18% revenue growth year-over-year is commendable, especially in the face of supply chain challenges. This indicates robust demand for Atrion's products, particularly the OEM fluid delivery products and MPS 3 consoles. On the other hand, operating income has decreased even when excluding the one-time inventory write-off. The write-off itself, due to a correction of an immaterial error, raises questions about inventory management and internal controls.

The gross margin contraction from 37.7% to 31.0% (adjusted) signals cost pressures or changes in sales mix, potentially affecting profitability. For investors, the promise to resume normal production in Q3 may serve as a potential inflection point for improved margins, yet the reliance on a few customers to right-size inventories introduces risk if their forecasts are off.

From a balance sheet perspective, the debt-free status and extdollar18.7 million in cash and investments provide financial stability. However, the 20% decline in net income and weaker investment portfolio performance could be stress points. Investors should weigh these aspects carefully against the company's longer-term prospects and market positioning.

The sales increase points to Atrion's strong market pull, particularly in the OEM and MPS 3 console segments. The resolution of supply chain issues and pent-up demand are key drivers here. However, it’s imperative to consider the broader implications of the OEM customer inventory right-sizing. This situation is reflective of the ongoing adjustments in the healthcare sector post-pandemic, which can lead to volatility in order patterns.

Atrion’s mention of normalized orders resuming in the second half of the year suggests a potential rebound in sales but also adds an element of uncertainty, contingent on customer actions. This information can be helpful for investors trying to gauge the company's near-term revenue prospects. The management’s strategy to mitigate the under absorption of overhead by reducing inventory could also signal enhanced operational efficiency going forward.

Lastly, the success of the MPS 3 consoles indicates a strategic pivot toward recurring revenue models via disposables, which could offer a stable and growing income stream. Investors interested in long-term value would find this aspect particularly noteworthy.

ALLEN, Texas, May 10, 2024 (GLOBE NEWSWIRE) -- Atrion Corporation (NASDAQ: ATRI) today announced its results for the first quarter ended March 31, 2024.

Revenues for the first quarter of 2024 totaled $47.3 million compared to $40.0 million for the same period in 2023. For the just ended quarter, operating income was $3.1 million, down $1.3 million from the comparable 2023 period, primarily due to a one-time inventory write-off, and net income was $2.8 million, down $0.7 million from the same period in 2023. First quarter 2024 diluted earnings per share were $1.59 compared to $1.98 for the first quarter of 2023.

Commenting on the results for the first quarter of 2024 compared to the prior year period, David Battat, President and CEO, stated, “Revenues grew 18% and operating income was up 22%, excluding the one-time inventory write off of $2.3 million in the first quarter of this year attributable to a correction of an immaterial error related to our consolidated financial statements for the year ended December 31, 2023. Revenues included strong double-digit increases in sales of OEM fluid delivery products and MPS 3 consoles. A record number of MPS 3 consoles were sold in the first quarter of this year, reflecting both strong market pull and pent-up demand now that supply chain shortages have been resolved. OEM sales for our products used in minimally invasive surgery have been negatively impacted as our customers continued to right-size their excess inventories. These customers have reported that their orders will resume to normal levels in the second half of this year.”

Mr. Battat added, “Gross margins for the quarter were 26.1% on a generally accepted accounting principles (GAAP) basis, but were 31.0% after adjusting for the inventory write-off compared to 37.7% in first quarter of 2023. This decline was driven primarily by two factors. First, in 2023, our inventory increased as many of our OEM customers repeatedly delayed orders as they realized they had overstocked in an effort to hedge against a prolonged supply-chain crisis. We continued to halt several production lines in the first quarter of 2024 so we could sell excess finished goods produced last year. While this resulted in under absorption of overhead, I am pleased to report that we made substantial progress reducing our inventory in the first quarter and expect to continue doing so in the second quarter of this year. We expect to resume normal production levels in the third quarter, which should result in improved margins. The second factor affecting gross margins was product mix, specifically the record number of MPS 3 consoles sold in the quarter. Although consoles sell at a lower gross margin, their placement results in a recurring revenue stream of disposables used in each surgery.”

Mr. Battat concluded, “Weaker performance in our investment portfolio in the current-year quarter also contributed to the 20% decline in net income for the quarter. As of March 31, 2024, cash and short- and long-term investments totaled $18.7 million. We remain debt free.”

Atrion Corporation develops and manufactures products primarily for medical applications. The Company’s website is www.atrioncorp.com.

Statements in this press release that are forward looking are based upon current expectations and actual results or future events may differ materially.  Such statements include, but are not limited to, Atrion's expectations regarding no further out-of-the ordinary write-offs or normal course-of-business write-offs of the size recognized in the first quarter of 2024, reduction of inventory in the second quarter of 2024, resumption of normal production levels in the third quarter of 2024 and improved margins, Words such as "expects," "believes," "anticipates," "forecasts," "intends," "should", "plans," "will" and variations of such words and similar expressions are intended to identify such forward-looking statements. Forward-looking statements contained herein involve numerous risks and uncertainties, and there are a number of factors that could cause actual results or future events to differ materially, including, but not limited to, the following: the risk that COVID-19 leads to further material delays and cancellations of, or reduced demand for, procedures in which our products are utilized; curtailed or delayed capital spending by hospitals and other healthcare providers; disruption to our supply chain; closures of our facilities; delays in training; delays in gathering clinical evidence; diversion of management and other resources to respond to COVID-19; the impact of global and regional economic and credit market conditions on healthcare spending; the risk that COVID-19 further disrupts local economies and causes economies in our key markets to enter prolonged recessions; changing economic, market and business conditions; acts of war or terrorism; the effects of governmental regulation; the impact of competition and new technologies; slower-than-anticipated introduction of new products or implementation of marketing strategies; implementation of new manufacturing processes or implementation of new information systems; our ability to protect our intellectual property; changes in the prices of raw materials; changes in product mix; intellectual property and product liability claims and product recalls; the ability to attract and retain qualified personnel; and the loss of, or any material reduction in sales to, any significant customers. In addition, assumptions relating to budgeting, marketing, product development and other management decisions are subjective in many respects and thus susceptible to interpretations and periodic review which may cause us to alter our marketing, capital expenditures or other budgets, which in turn may affect our results of operations and financial condition. The foregoing list of factors is not exclusive, and other factors are set forth in the Company's filings with the Securities and Exchange Commission. The forward-looking statements in this press release are made as of the date hereof, and we do not undertake any obligation, and disclaim any duty, to supplement, update or revise such statements, whether as a result of subsequent events, changed expectations or otherwise, except as required by applicable law.

Contact:Cindy Ferguson
Vice President and Chief Financial Officer
(972) 390-9800
  


ATRION CORPORATION
UNAUDITED CONSOLIDATED STATEMENTS OF INCOME
(In thousands, except per share data)
 
 Three Months Ended
March 31,
 
  2024   2023  
Revenues$ 47,334  $39,993  
Cost of goods sold 34,983   24,912  
Gross profit 12,351   15,081  
Operating expenses 9,209   10,611  
Operating income 3,142   4,470  
     
Interest and dividend income  156    240  
Other investment income (loss)  (109)   (721) 
Other income  14    10  
Income before income taxes  3,203   3,999  
Income tax provision  (411)   (514) 
Net income $2,792  $3,485  
     
Income per basic share$1.59  $1.98  
     
Weighted average basic shares
     outstanding
 1,760   1,762  
     
     
Income per diluted share$1.59  $1.98  
     
Weighted average diluted shares
     outstanding
 1,761   1,763  
 



ATRION CORPORATION
CONSOLIDATED BALANCE SHEETS
(In thousands)
 
 March 31, December 31, 
ASSETS 2024  2023 
     
Current assets:    
Cash and cash equivalents$7,135 $3,565 
Short-term investments 2,760  2,691 
Total cash and short-term investments 9,895  6,256 
Accounts receivable 25,116  23,029 
Inventories 75,000  82,307 
Prepaid expenses and other 2,503  3,173 
Total current assets 112,514  114,765 


Long-term investments
 8,853  8,165 


Property, plant and equipment, net
 124,608  125,347 
Other assets 12,652  12,548 
     
 $258,627 $260,825 
     
     
LIABILITIES AND STOCKHOLDERS’ EQUITY    
     
Current liabilities 12,252  12,621 
Other non-current liabilities 4,452  5,315 
Stockholders’ equity 241,923  242,889 
     
 $258,627 $260,825 
 


ATRION CORPORATION
NON-GAAP FINANCIAL INFORMATION
(In thousands)
 

This release includes references to non-GAAP gross margin and operating income excluding a one-time inventory write-off. These financial measures are not prepared in accordance with GAAP. The gross profit excluding inventory write-off and operating income excluding inventory write-off are calculated by adding the one-time inventory write-off to our most directly comparable GAAP measure cost of goods sold.

We believe that these non-GAAP measures provide insight into our operating income performance. However, our non-GAAP financial measures may not be comparable to similarly titled non-GAAP financial measures used by other companies. These non-GAAP financial measures have limitations as an analytical tool and should not be considered in isolation or as a substitute for GAAP financial measures. and are supplemental to the comparable GAAP measures.

Reconciliation to the most directly comparable GAAP measures is provided in the table below.

 Three Months Ended
March 31,
   
  2024   2023  Change 
Revenues$ 47,334  $39,993  18%  
Cost of goods sold 34,983   24,912    
Gross profit 12,351   15,081    
Add: inventory write-off 2,306   -    
Gross profit excluding inventory write-off 14,657   15,081    
       
Gross margin excluding inventory write-off 31.0%   37.7%    
       
Operating income 3,142   4,470    
Add: inventory write-off 2,306   -    
Operating income excluding inventory write-off 5,448   4,470  22%  

FAQ

What were Atrion 's first quarter 2024 revenues?

Atrion reported revenues of $47.3 million for the first quarter of 2024.

What caused the decline in operating income for Atrion in the first quarter of 2024?

The decline in operating income was primarily due to a one-time inventory write-off.

What was Atrion 's net income for the first quarter of 2024?

Atrion reported a net income of $2.8 million for the first quarter of 2024.

What was the diluted earnings per share for Atrion in the first quarter of 2024?

Atrion reported diluted earnings per share of $1.59 for the first quarter of 2024.

What is the total cash and investments of Atrion as of March 31, 2024?

As of March 31, 2024, Atrion had total cash and investments of $18.7 million.

Atrion Corp

NASDAQ:ATRI

ATRI Rankings

ATRI Latest News

ATRI Stock Data

809.44M
1.76M
23.37%
71.86%
2.53%
Medical Instruments & Supplies
Surgical & Medical Instruments & Apparatus
Link
United States of America
ALLEN